Clinical Trials Logo

HIV/HCV Coinfection clinical trials

View clinical trials related to HIV/HCV Coinfection.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02762383 Terminated - HIV/HCV Coinfection Clinical Trials

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

Start date: March 2005
Phase: Phase 3
Study type: Interventional

This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Participants with HIV/HCV who do not show negative or reduced HCV ribonucleic acid (RNA) after at least 12 weeks of treatment with peginterferon alfa-2a plus ribavirin will receive a low dose of peginterferon alfa-2a for 18 months. The primary objective is to evaluate safety and tolerability. Secondary objectives are to evaluate histological, virological, and biochemical effects.